IP Library Granted Patent US 10,047,120
Granted Patent B2
US 10,047,120 · App. 14/421,666 · Granted Aug 14, 2018

Method for producing a composition for treating a tooth lesion

Inventors: Michael Hug (Zofingen, CH); Dominikus Amadeus Lysek (Windisch, CH)
Assignee: Credentis AG
C07K7/06A61C5/68A61K6/0017C07K1/00A61K38/00C03C2205/06Y10S522/908
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,047,120
App. No.
14/421,666
Granted
Aug 14, 2018
Kind
B2
Abstract

The invention relates to a method for preparing a composition for treating a tooth lesion, said composition comprising peptides that are capable of undergoing self-assembly at a certain pH. The compositions of the invention are highly suitable for being used in the medical field, in particular for remineralizing a tooth lesion such as a subsurface caries lesion.

Claims (45)

1. A composition in lyophilized form comprising

a peptide that undergoes self-assembly at a pH value below 7.5, wherein the peptide is predominantly in a monomeric form;

a non-reducing sugar; and

a non-volatile buffer;

wherein upon reconstitution of the composition in water, a solution with an ionic strength of less than 0.15 having a pH that is 0.1 to 0.5 pH units above the pH at which the peptide starts to undergo self-assembly is obtained in which the peptide is predominantly present in a monomeric form.

2. The composition of claim 1 , wherein said peptide comprises the sequence of SEQ ID NO:3.

3. The composition of claim 1 , wherein said peptide comprises the sequence of SEQ ID NO: 4 or SEQ ID NO: 5.

4. The composition of claim 1 , wherein said peptide comprises the sequence depicted in SEQ ID NO:1 or SEQ ID NO:2 or a sequence having at least 80% sequence identity thereto.

5. The composition of claim 1 , wherein at least 70% of the peptide is present in monomeric form.

6. The composition of claim 1 produced by a method comprising the following steps:

a) providing a solution comprising a peptide that starts to undergo self-assembly at a pH below 7.5, wherein said solution comprises a buffer which is non-volatile during lyophilisation and which provides a pH which is 0.1 to 0.5 pH units above the pH at which the peptide starts to undergo self-assembly;

b) adding a compound that increases the pH of the solution to 8.0 or higher, said compound being sufficiently volatile to be removed during lyophilization; and

c) lyophilizing the solution to produce a lyophilisate that results in a solution having a pH that is 0.1 to 0.5 pH units above the pH at which the peptide starts to undergo self-assembly if the lyophilisate is dissolved in water, said solution comprising the peptide predominantly in its monomeric state.

7. The composition of claim 6 , wherein the concentration of the peptide in step a) is 0.1-100 mg/mL, the concentration of the non-volatile buffer in step a) is less than 150 mM, and the ionic strength is less than 0.15.

8. The composition of claim 1 , wherein the non-volatile buffer maintains an essentially neutral pH range.

9. The composition of claim 1 , wherein the non-volatile buffer comprises TAPS ({[tris(hydroxymethyl)methyl] amino}propanesulfonic ac-id), Bicine (N,N-bis (2-hydroxyethyl) glycine), Tris(Tris(hydroxymethyl)-aminomethan), Tricine (N-tris(hydroxymethyl) methylglycine), TAPSO (3-[N-Tris(hydroxyl-methyl)methylamino]-2-hydroxypropanesulfonic acid), HEPES (4-2-hydroxy¬ethyl-1-piperazineethanesulfonic acid), TES (2-{[tris(hydroxyme-thyl)methyl]amino}ethanesulfonic acid), MOPS (3-(N-morpholino) propanesulfonic acid), PIPES (piperazine-N,N′-bis (2-ethanesulfonic acid)), Cacodylate (dimethylarsinic acid), SSC (saline sodium citrate), MES (2-(N-morpholino)ethane-sulfonic acid), or any combination thereof.

10. The composition of claim 1 , wherein the non-volatile buffer comprises citric acid or phosphoric acid in combination with potassium hydroxide, ammonium hydroxide, potassium phosphate di- and tri-basic, Tris, triethanolamine, polyethylenimine, or any combination thereof.

11. The composition of claim 1 , wherein the non-volatile buffer is TRIS.

12. The composition of claim 1 , wherein the concentration of the peptide in the solution obtained after reconstitution of the composition in water is 0.1-100 mg/mL, the concentration of the non-volatile buffer is less than 1500 mM and the ionic strength is less than 0.15.

13. The composition of claim 12 , wherein the concentration of the peptide in the solution obtained after reconstitution of the composition in water is 1-20 mg/mL.

14. The composition of claim 13 , wherein the non-volatile buffer is TRIS in a concentration of 10 mM or lower.

15. A method, comprising

a) reconstituting the composition of claim 1 in water, and

b) filling a tooth lesion or remineralizing a tooth surface, caries lesion, or combination thereof, with the reconstituted composition.

16. The method of claim 15 , wherein the tooth lesion comprises a sub-surface caries lesion.

17. The method of claim 15 , wherein the caries lesion comprises a sub-surface caries lesion.

18. A method for producing a composition suitable for treating a tooth lesion, comprising

a) providing a solution comprising a peptide that starts to undergo self-assembly at a pH below 7.5, wherein said solution comprises a buffer which is non-volatile during lyophilisation and which provides a pH which is 0.1 to 0.5 pH units above the pH at which the peptide starts to undergo self-assembly;

b) adding a compound that increases the pH of the solution to 8.0 or higher, said compound being sufficiently volatile to be removed during lyophilization; and

c) adding a non-reducing sugar;

d) lyophilizing the solution to produce a lyophilisate; and

e) dissolving the lyophilizate in water to obtain a solution with an ionic strength of less than 0.15 having a pH that is 0.1 to 0.5 pH units above the pH at which the peptide starts to undergo self-assembly, said solution comprising the peptide predominantly in its monomeric state.

19. The method of claim 18 , wherein said pH in step b) is increased to pH 8-9.

20. The method of claim 18 , wherein said non-reducing sugar is selected from the group consisting of mannitol, sorbitol, sucrose, and trehalose.

21. The method of claim 18 , wherein said compound in step b) is selected from the group consisting of ammonia, 2-aminoethanol, 4-methylmorpholine, and pyridine.

22. The method of claim 18 , wherein more than 90% of the compound of step b) is removed from the solution upon lyophilization.

23. The method of claim 18 , wherein the composition obtained in step c) is further mixed with a vehicle suitable for being applied to a tooth surface.

24. The method of claim 23 , wherein the vehicle is a hydrogel.

25. The method of claim 18 , wherein the solution in step a) comprises TRIS in a concentration of 40 mM or lower.

26. The method claim 25 , wherein the TRIS is in a concentration of 20 mM or lower.

27. The method of claim 26 , wherein the TRIS is in a concentration of 10 mM or lower.

28. The method of claim 18 , wherein said peptide comprises the sequence of SEQ ID NO: 3.

29. The method of claim 18 , wherein said peptide comprises the sequence of SEQ ID NO: 4 or SEQ ID NO: 5.

30. The method of claim 18 , wherein said peptide comprises the sequence depicted in SEQ ID NO: 1 or SEQ ID NO: 2 or a sequence having at least 80% sequence identity thereto.

31. The method of claim 18 , wherein said pH in step b) is increased to pH 8.5.

Assignments (2)
SECURITY INTEREST Recorded Feb 7, 2025
From: CREDENTIS AG; SWISS SHINE BEAUTY AG; VVARDIS AG
To: ORBIMED ROYALTY & CREDIT OPPORTUNITIES IV, LP
Reel/Frame 070139/0560 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 16, 2015
From: HUG, MICHAEL; LYSEK, DOMINIKUS AMADEUS
To: CREDENTIS AG
Reel/Frame 035420/0876 →
Priority Claims (1)
EP 12180578 · Aug 15, 2012 · regional
Continuity (1)
Related Publication 20150232511A1 · Aug 20, 2015
Cited By (2)
US 12,280,087 US 12,485,078